Pharmaceutical products

Country: Norway
Language: EN
Customer: Sykehusinnkjøp HF
Number: 4228132
Publication date: 13-09-2017
Source: TED
Deadline: 26 days
Tags: Pharmaceutical products

Description

13/09/2017    S175    - - Supplies - Voluntary ex ante transparency notice - Contract award without prior publication 

Norway-Vadsø: Pharmaceutical products

2017/S 175-359739

Voluntary ex ante transparency notice

Supplies

Directive 2014/24/EU

Section I: Contracting authority/entity

I.1)Name and addresses
Sykehusinnkjøp HF
916879067
Tollbugata 7
Vadsø
9800
Norway
Contact person: Kjetil R. Flateby
E-mail: flkj@sykehusinnkjop.no
NUTS code: NO

Internet address(es):

Main address: https://permalink.mercell.com/73313425.aspx

Address of the buyer profile: http://www.sykehusinnkjop.no/

I.4)Type of the contracting authority
Ministry or any other national or federal authority, including their regional or local subdivisions
I.5)Main activity
Health

Section II: Object

II.1)Scope of the procurement
II.1.1)Title:

LIS 1701-2 Additional Agreements.

Reference number: 2017/1220
II.1.2)Main CPV code
33600000
II.1.3)Type of contract
Supplies
II.1.4)Short description:

The procurement comprises the purchase of the active ingredients N01BB01 Bupivacaine and L01AA03 Melphalan for relevant health authorities in Norway (see the attached Excel file). The Contracting Authority intends to sign agreements with Aspen Pharma and Macure Pharma ApS.

The procurement of N01BB01 Bupivacaine is a consequence of the termination of the existing agreements on the active ingredient N01BB01 under LIS 1701 A, due to long term and continued delivery failure.

The procurement of L01AA03 is to ensure delivery of the active ingredient until a new procurement takes place. The start date for new agreements is 1.2.2018.

II.1.6)Information about lots
This contract is divided into lots: no
II.1.7)Total value of the procurement (excluding VAT)
Value excluding VAT: 4 000 000.00 NOK
II.2)Description
II.2.1)Title:
II.2.2)Additional CPV code(s)
II.2.3)Place of performance
NUTS code: NO01
II.2.4)Description of the procurement:

To cover the health authorities" need for the active ingredients Bupivacaine and Melphalan, it is necessary to enter into new framework agreements. A new procurement process will take about 2 months to execute, and a new service provider will additionally need a lead time of 3 months from awarding of the agreement until delivery can occur. A new agreement will therefore most likely not be in place before December, after a regular tender process. With the execution of a regular tender process, the health authorities must wait an unreasonable length of time before the new supplier is in place. The existing agreements under LIS 1701 A are in place until 31.1.2018, and a new agreement for the active ingredient Bupivacaine will therefore, after a regular tender process, only have a duration of a little under 2 months. New procurement processes have been started for this entire contract area, the new framework agreements shall apply from 1.2.2018. It is therefore considered unlikely that there will be any interested parties in the supplier market to participate in a regular tender process for only the active ingredients Bupivacaine and Melphalan, when the agreement period is under 2 months. In regard to the purchase of the active substances, the Contracting Authority has made enquiries to all suppliers in the market that the Contracting Authority has knowledge of, and who may be relevant for the delivery of this active substance. Aspen Pharma and Macure Pharma ApS are the only suppliers who have confirmed that they can deliver.

On this basis, the Contracting Authority means that it would be impossible to uphold the deadlines for an open tender contest as a consequence of circumstances for which the Contracting Authority is not responsible, and that the Contracting Authority cannot have foreseen, and that therefore there is statutory basis to enter into an agreement with Aspen Pharma and Macure Pharma ApS.

II.2.5)Award criteria
Price
II.2.11)Information about options
Options: no
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

Section IV: Procedure

IV.1)Description
IV.1.1)Type of procedure
Award of a contract without prior publication of a call for competition in the Official Journal of the European Union in the cases listed below
  • The procurement falls outside the scope of application of the directive
Explanation:

To cover the health authorities" need for the active ingredients Bupivacaine and Melphalan, it is necessary to enter into new framework agreements. A new procurement process will take about 2 months to execute, and a new service provider will additionally need a lead time of 3 months from awarding of the agreement until delivery can occur. A new agreement will therefore most likely not be in place before December, after a regular tender process. With the execution of a regular tender process, the health authorities must wait an unreasonable length of time before the new supplier is in place. The existing agreements under LIS 1701 A are in place until 31.1.2018, and a new agreement for the active ingredient Bupivacaine will therefore, after a regular tender process, only have a duration of a little under 2 months. New procurement processes have been started for this entire contract area, the new framework agreements shall apply from 1.2.2018. It is therefore considered unlikely that there will be any interested parties in the supplier market to participate in a regular tender process for only the active ingredients Bupivacaine and Melphalan, when the agreement period is under 2 months. In regard to the purchase of the active substances, the Contracting Authority has made enquiries to all suppliers in the market that the Contracting Authority has knowledge of, and who may be relevant for the delivery of this active substance. Aspen Pharma and Macure Pharma ApS are the only suppliers who have confirmed that they can deliver. On this basis, the Contracting Authority means that it would be impossible to uphold the deadlines for an open tender contest as a consequence of circumstances for which the Contracting Authority is not responsible, and that the Contracting Authority cannot have foreseen, and that therefore there is statutory basis to enter into an agreement with Aspen Pharma and Macure Pharma ApS.

IV.1.3)Information about framework agreement
The procurement involves the establishment of a framework agreement
IV.1.8)Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: yes
IV.2)Administrative information
IV.2.1)Previous publication concerning this procedure

Section V: Award of contract/concession

Contract No: LIS 1701-2
Title:

LIS 1701-2 Additional Agreements.

V.2)Award of contract/concession
V.2.1)Date of contract award decision:
04/09/2017
V.2.2)Information about tenders
The contract has been awarded to a group of economic operators: yes
V.2.3)Name and address of the contractor/concessionaire
Macure Pharma ApS
Hejrevej 39
Copenhagen
2400
Denmark
NUTS code: NO01
The contractor/concessionaire will be an SME: no
V.2.3)Name and address of the contractor/concessionaire
Aspen Pharma Nordic
Borupvang 3
Ballerup
2750
Denmark
NUTS code: NO01
The contractor/concessionaire will be an SME: no
V.2.4)Information on value of the contract/lot/concession (excluding VAT)
Total value of the contract/lot/concession: 2 000 000.00 NOK
V.2.5)Information about subcontracting
The contract/lot/concession is likely to be subcontracted

Section VI: Complementary information

VI.3)Additional information:
VI.4)Procedures for review
VI.4.1)Review body
Klagenemda for offentlige anskaffelser
Postboks 439 Sentrum
Bergen
5805
Norway
VI.4.2)Body responsible for mediation procedures
VI.4.3)Review procedure
VI.4.4)Service from which information about the review procedure may be obtained
VI.5)Date of dispatch of this notice:
09/09/2017

Other tenders from Norway за for this period

Marine equipment Source: TED

Software package and information systems Source: TED

Vegetables, fruits and nuts Source: TED

Laboratory, optical and precision equipments (excl. glasses) Source: TED

Devices for the disabled Source: TED